Stocks Health care JAGX
NASDAQ · Health careJaguar Health, Inc. (JAGX)
Jaguar Health, Inc. brought in $27.8M of revenue over the twelve months to June 30, 2026, up 135.5% from a year earlier. It posted a net loss of $52.4M. At June 30, 2026 it held $3.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 19, 2026.
Key facts about Jaguar Health, Inc.
- Net worth
- Jaguar Health, Inc. has a market value (market cap) of $2.2M at the latest share price, and shareholders' equity of $4.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $11.5M (-1.5% year on year), with a net loss of $53.6M. Over the 12 months to June 30, 2026: revenue $27.8M, net loss $52.4M.
- Cash flow
- In fiscal 2025 operations used $23.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 19, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Jaguar Health, Inc. does
Jaguar Health, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JAGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $11.5M | -$53.6M | -$22.97 | n/a |
| 2024 | $11.7M | -$38.5M | -$130.69 | -$29.4M |
| 2023 | $9.8M | -$41.9K | -$2,678.17 | n/a |
| 2022 | $12M | -$48.4K | -$54,131.95 | -$33.2M |
| 2021 | $4.3M | -$52.6K | -$131,993.38 | -$35M |
| 2020 | $9.4M | -$33.8M | -$335,576.40 | -$15.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where JAGX ranks in Health care
Latest SEC filings
What Jaguar Health, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Material agreement8-KJaguar Health extended its debt maturity and royalty payment start dates to January 2027 and declared a special Series R preferred stock dividend.
- September 29, 2026Form PRER14A filing PRER14A
- September 28, 2026Material agreement8-KJaguar Health entered into an exchange agreement to reduce its secured note balance by $3,400,000 in exchange for 481,584 shares of common stock.
- September 25, 2026Material agreement8-KJaguar Health issued common shares to Streeterville Capital to reduce and extinguish secured promissory notes.
- September 24, 2026Passive stake changed SCHEDULE 13G/A
- September 24, 2026Material agreement8-KJaguar Health agreed to issue 547,898 shares of common stock to Streeterville Capital to reduce debt by $5,049,909.26.
- September 21, 2026
- September 18, 2026Preliminary proxy statement PRE 14A
- September 15, 2026
- September 15, 2026
Insider trades
What the people running Jaguar Health, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| December 11, 2025 | Micek JohnDirector | Received as pay | 7,377 | - |
| December 11, 2025 | Conte Lisa ASee Remarks, Director | Received as pay | 28,592 | - |
| December 11, 2025 | Wolin Jonathan S.See Remarks | Received as pay | 11,740 | - |
| December 11, 2025 | King Steven R.See Remarks | Received as pay | 11,740 | - |
| December 11, 2025 | Lizak Carol R.Chief Financial Officer | Received as pay | 11,740 | - |
| December 11, 2025 | Jayasuriya AnulaDirector | Received as pay | 5,870 | - |
| December 11, 2025 | Siegel Jonathan B.Director | Received as pay | 7,377 | - |
| December 11, 2025 | Bochnowski James JDirector | Received as pay | 6,363 | - |
Who owns JAGX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Joshua Mailman13G, passive | 9.99% | September 24, 2026 |
| John Fife and Fredrick Waid13G, passive | 9.9% | January 29, 2025 |
| Iliad Research & Trading, L.P.13G, passive with 3 related filers | 9.8% | December 11, 2025 |
Largest institutional holders
Insiders
9 insiders reported holding 104,114 shares in total, about $47.5K at the last price.
| Holder | Shares |
|---|---|
| Conte Lisa ASee Remarks, Director | 29,258 |
| Chaturvedi Pravin RChief Scientific Officer | 11,938 |
| Wolin Jonathan S.See Remarks | 11,938 |
| Lizak Carol R.Chief Financial Officer | 11,911 |
| King Steven R.See Remarks | 11,885 |
| Micek JohnDirector | 7,430 |
| Siegel Jonathan B.Director | 7,423 |
| Bochnowski James JDirector | 6,415 |
| Jayasuriya AnulaDirector | 5,916 |
Questions about JAGX
What does Jaguar Health, Inc. do?
Jaguar Health, Inc. is a company in the Health care sector, listed on NASDAQ as JAGX. Its shares trade on NASDAQ under the ticker JAGX.
What is Jaguar Health, Inc.'s net worth?
Jaguar Health, Inc. has a market value (market cap) of $2.2M at the latest share price, and shareholders' equity of $4.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Jaguar Health, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $52.4M on revenue of $27.8M.
How much revenue does Jaguar Health, Inc. make?
Over the twelve months to June 30, 2026 Jaguar Health, Inc. reported revenue of $27.8M. That is 135.5% more than a year earlier.
When did Jaguar Health, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 19, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from October 5, 2026.
Similar companies
Compare JAGX with
Follow JAGX
Get an email when Jaguar Health, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Jaguar Health, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.